# TB-500: establish the material before the claim > 03 TB-500 | Recovery & Tissue Repair research peptides — Clover Peptides Review — Recovery & Tissue Repair research peptides: Most related efficacy findings concern full-length thymosin beta-4; they do not establish repair by the TB-500 fragment. **03 TB-500 / CLOVER PEPTIDES REVIEW** Most related efficacy findings concern full-length thymosin beta-4; they do not establish repair by the TB-500 fragment. ## The finding, in plain English Human repair by the TB-500 fragment is not established. Much of the research used to support its reputation studied a different material: full-length thymosin beta-4, the parent protein. A shared piece of a protein does not make the fragment and the whole protein interchangeable. [13][15] TB-500 refers here to the synthetic Ac-LKKTETQ fragment. The parent protein binds actin, a protein involved in the cell's internal framework and movement. Research on that parent protein examines cell movement, wound-related processes and blood-vessel growth. Those mechanisms help explain scientific interest, but they are not proof of recovery from a human muscle tear. [15][17] This entry names the material used before discussing where a finding occurred. A brain-injury experiment in rats and a safety study in healthy people appear in the record. Both concern thymosin beta-4. Neither establishes that the TB-500 fragment safely repairs tissue throughout the human body. [14][16] ## A fragment with an important identity gap The full name in this digest is TB-500, an N-acetylated fragment of thymosin beta-4. Ac-LKKTETQ identifies the fragment's amino-acid sequence and chemical modification. The actin-binding region explains why it is linked to the parent protein in repair discussions. It does not show that every activity of the parent survives isolation of that region. Full-length thymosin beta-4 is an endogenous protein, meaning it occurs naturally in the body. The fragment is a separate experimental material. The supplied corpus explicitly distinguishes them, because commercial naming and broad “thymosin” claims often blur that boundary. The parent-protein review and structural study establish biological rationale; they do not supply a controlled human efficacy trial of the fragment. [15][17] Product identity also matters to safety interpretation. An unverified preparation cannot inherit the evidence attached to a defined study material. ## Actin binding explains interest, not equivalence Actin changes between individual units and assembled structures within cells. Full-length thymosin beta-4 binds globular actin, the individual units, and helps maintain a pool of unassembled actin. Structural work shows binding that caps the monomer at both ends, preventing polymerization, or assembly into a filament. [17] The review literature connects the parent protein with cell migration, stem-cell activity, reduced apoptosis and altered scar formation. **Apoptosis** is programmed cell death. It also discusses angiogenesis, the growth of new blood vessels, as part of the rationale for wound, corneal, heart and nervous-system research. [15] These mechanisms involve a repair environment, including mobile cells and vessel-forming cells. A mechanism does not specify how far repair extends from an injury, and a parent-protein mechanism does not establish the isolated fragment's human behavior. The spatial map must retain both limits. ## The studies concern different materials and questions **Evidence appraisal.** A Sports Medicine narrative review published in 2026 discusses approved and unapproved peptides for musculoskeletal injury and performance. It includes TB-500/thymosin beta-4 and BPC-157 among the unapproved compounds. Favorable animal findings are accompanied by scarce rigorous human safety evidence, potential for serious harm and limited regulatory oversight. This is a warning about evidence maturity, not an endorsement of fragment efficacy. [13] **Rat brain-injury study.** In a Wistar-rat stroke model, thymosin beta-4 improved neurological function in some treatment groups but not the highest-dose group. Significant improvement was reported from day 14 through day 56. The finding was non-monotonic: increasing the experimental amount did not produce steadily greater benefit. It concerns the parent protein and a defined brain-injury model, not TB-500-assisted exercise recovery. [14] **Mechanism review.** The thymosin beta-4 review assembles evidence on cell mobilization, inflammatory signaling, angiogenesis and reduced myofibroblast numbers. Myofibroblasts are cells involved in scar formation. The proposed applications include dermal wounds, corneal injury and heart or central-nervous-system repair. A collection of applications does not demonstrate simultaneous repair of distant organs in the same subject. [15] **Human safety study.** A randomized, placebo-controlled early-phase study involved 40 healthy volunteers receiving intravenous synthetic thymosin beta-4. The study included repeated administration for 14 days. It reported infrequent mild or moderate adverse events and no serious adverse events or dose-limiting toxicities. It examined full-length material, not TB-500, and healthy volunteers rather than injury-repair efficacy. [16] **Structural finding.** X-ray crystallography of a thymosin beta-4-containing hybrid bound to actin established a 1:1 complex and the dual-end-capping mechanism. That biochemical result helps explain the parent protein's actin-buffering action. It does not measure a wound, a neighboring tissue or a recovered human organ. [17] ## Reported effects and unresolved safety Community recovery reports are anecdotal, not clinical evidence. They include easier movement, less joint pain or stiffness, more flexibility, reduced soreness, and wounds seeming to heal faster. Hair-growth accounts are less consistent and can involve other interventions. A subjective improvement cannot identify the fragment's action or establish structural healing. Adverse community accounts are anecdotal, not clinical evidence. Reports include local redness, swelling or aching, fatigue, headache, lightheadedness, a flu-like feeling, nausea and mood changes. Some describe greater awareness of an existing injury. These are not controlled safety measurements and do not establish incidence or causation. Human safety of the fragment remains essentially unstudied in controlled trials. The parent-protein volunteer study cannot close that gap. Research-material identity and purity add uncertainty. The supplied cautions also distinguish biological repair markers from functional improvement; more regeneration-related activity is not automatically better strength or organ function. [13][16] Pro-migration and pro-angiogenic biology raises theoretical tumor-related concerns. Uncertain effects around clotting or surgery and absent safety data in pregnancy, breastfeeding and younger populations are precautionary gaps, not established fragment-specific adverse outcomes. The parent-protein mechanisms provide a reason to ask safety questions; they do not quantify those risks. [15] The supplied status summary records no FDA-approved TB-500 indication and identifies TB-500 and thymosin beta-4 as WADA-prohibited. This digest gives neither human-use instructions nor sporting clearance. ## A spatial map with the identity boundary intact Wound, cornea, heart and brain are separate research locations in the parent-protein literature. An organ distant from a skin injury is not automatically repaired because it appears as the injury site in a different study. The rat stroke result concerns the injured brain; the human trial concerns systemic safety in healthy volunteers. [15][14][16] Adjacent repair cells and blood vessels may be part of a proposed mechanism, but surrounding-tissue endpoints need separate measurement. TB-500's position in the [comparison](/compare) therefore carries a persistent identity qualification: parent-protein findings are informative context, while controlled human repair and safety for the isolated fragment remain unestablished. [13][17] --- Clover Peptides Review is an independent digest of repair findings at the injury, its margins and distant organs, with no peptide sales or medical advice.